Cargando…
Biomarker Testing for Actionable Alterations in NSCLC—Perspectives from US-Based Academic and Community Oncologists: A Podcast
The identification of actionable oncogenic driver mutations in patients with non-small cell lung cancer impacts therapy selection, and appropriate therapy administration results in improvements in clinical outcomes. Although biomarker testing for actionable oncogenic driver mutations is recommended...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611827/ https://www.ncbi.nlm.nih.gov/pubmed/37779172 http://dx.doi.org/10.1007/s12325-023-02664-1 |